Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,250 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Leslie Norwalk sold 1,250 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $182.01, for a total transaction of $227,512.50. Following the sale, the director directly owned 1,588 shares of the company’s stock, valued at $289,031.88. The trade was a 44.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Up 2.6%

Neurocrine Biosciences stock opened at $185.50 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $122.14 and a twelve month high of $186.12. The stock has a market cap of $18.65 billion, a P/E ratio of 28.58, a P/E/G ratio of 0.76 and a beta of 0.39. The company’s 50-day moving average price is $167.61 and its two-hundred day moving average price is $146.25.

Institutional Trading of Neurocrine Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC grew its holdings in Neurocrine Biosciences by 18.0% during the 4th quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock worth $462,652,000 after acquiring an additional 498,058 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Neurocrine Biosciences by 8.0% in the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock valued at $318,665,000 after purchasing an additional 180,100 shares during the period. Geode Capital Management LLC raised its position in Neurocrine Biosciences by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock worth $291,342,000 after purchasing an additional 34,457 shares during the last quarter. Los Angeles Capital Management LLC lifted its holdings in Neurocrine Biosciences by 7.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock worth $178,248,000 after buying an additional 88,522 shares during the period. Finally, Northern Trust Corp raised its position in shares of Neurocrine Biosciences by 31.9% during the fourth quarter. Northern Trust Corp now owns 1,221,184 shares of the company’s stock worth $173,201,000 after acquiring an additional 295,470 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NBIX has been the subject of a number of research reports. Weiss Ratings raised Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday. Guggenheim increased their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Sanford C. Bernstein began coverage on shares of Neurocrine Biosciences in a research report on Friday, May 22nd. They issued an “outperform” rating and a $221.00 price target for the company. Morgan Stanley increased their price target on Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $185.00 target price on shares of Neurocrine Biosciences in a report on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $194.05.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.